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C ancer is a genetic dis-ease, resulting from germline (inherited) or somatic (acquired) 
mutations in DNA. Although most 
cancers arise from acquired DNA 
damage over an individual’s life-
time, 5% to 10% of cancer diag-
noses are caused by an inherited 
gene mutation (Mauer, Pirzadeh-
Miller, Robinson, & Euhus, 2014). 
Traditionally, genetic testing for 
hereditary cancer risk follows a 
sequential single-gene approach 
through Sanger sequencing meth-
ods. Next-generation sequencing 
(NGS) technology has expanded 
testing options to include multi-
gene panels.
Multigene panel testing refers 
to the parallel sequencing of mul-
tiple prespecified genes to identify 
pathologic DNA variation (Hall, For-
man, Pilarski, Wiesner, & Giri, 2014). 
Many cancer susceptibility gene 
panels are directed toward testing 
for a specific type of cancer (e.g., 
Ambry Genetics offers the Breast-
Next hereditary cancer panel for 
breast cancer) or a hereditary cancer 
syndrome (e.g., GeneDx offers the 
Lynch syndrome/colorectal cancer 
high-risk panel). Other comprehen-
sive gene panels cast a wider net and 
include genes implicated in a vari-
ety of hereditary cancer syndromes 
(e.g., Comprehensive Cancer Panel 
offered by GeneDx).
The identification of an in-
herited genetic component as-
sociated with cancer risk can 
have a significant impact on risk- 
reduction and surveillance mea-
sures, as well as on treatment deci-
sions if cancer is present. In some 
cases, multigene panels for inherited 
cancer risk have proved to be a more 
time- and cost-efficient approach 
and are predicted to be increasingly 
utilized by practitioners. 
However, there are a number of 
issues and challenges to consider 
when counseling and testing for in-
herited cancer risk, and they become 
exceedingly more complex when 
shifting from single to multigene 
testing. Technologic advances have 
outpaced our understanding of the 
human genome, as genetic varia-
tions are being rapidly discovered in 
which their effect on gene function 
and clinical significance have yet to 
be determined.
Genetic counselors play a sig-
nificant role in recognizing and de-
ciphering the genetic challenges in J Adv Pract Oncol 2016;7:394–407
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cancer care. But in clinical practices without ge-
netic specialists, advanced practitioners (APs) are 
well positioned to facilitate the inclusion of genet-
ics and genomics into patient care. However, cur-
rently there is a gap in knowledge and preparation 
to assume the role in its entirety, especially with 
the rapid advances in genetic testing technology 
(Greco, Tinley, & Seibert, 2011). Advanced prac-
titioners must become increasingly proficient in 
recognizing familial cancer patterns suggestive of 
hereditary disease, facilitating proper ordering of 
genetic tests, and interpreting test results, as well 
as have current knowledge of the ethical, legal, 
psychosocial, and financial implications of genetic 
testing for cancer risk. This article provides an 
overview of multigene panel testing for hereditary 
cancer risk and offers two case examples to high-
light the clinical considerations, benefits, limita-
tions, and insurance challenges encompassed in 
this new approach to genetic testing.
OVERVIEW OF MULTIGENE PANELS
Completion of the Human Genome Project 
has opened the doors for significant clinical ad-
vances with a tremendous impact on cancer care, 
particularly in the ability to detect germline gene 
mutations that confer an increased cancer risk. 
Indeed, research has identified mutations in many 
genes that contribute to more than 50 different 
hereditary cancer syndromes. Identification of 
genetic cancer risk has traditionally been done 
through the application of single-gene testing, 
but technologic advances have led to the develop-
ment and application of multigene panel testing, 
in which a large array of genes can be tested at the 
same time in a single diagnostic platform to pos-
sibly reveal genetic information not available in a 
single-gene test.
Multigene panels consist of a varying number 
of preselected genes, ranging from 5 to more than 
60, and can comprise genes with differing levels 
of penetrance (see Table 1). Penetrance is associ-
ated with disease susceptibility; the higher the 
penetrance, the greater the risk of disease associ-
ated with carrying that gene mutation (see Figure 
1). For example, an inherited mutation in a BRCA1 
gene carries a 65% to 70% lifetime risk of breast 
cancer; thus, a BRCA1 mutation is classified as a 
high-penetrance susceptibility gene. Conversely, 
gene mutations (or variants) with low penetrance 
are not only more common, but also contribute 
less to disease risk.
The clinical utility of identifying germline 
high-penetrance gene mutations is strong, as clear 
recommendations for cancer prevention, surveil-
lance, and management exist within the National 
Comprehensive Cancer Network (NCCN) Guide-
lines. Conversely, the clinical utility of identifying 
germline low-penetrance gene mutations has not 
been established; thus, clinical practice recom-
mendations are nonexistent for them. Consensus 
guidelines for screening or management are just 
beginning to be established for some moderate-
penetrance genes (see Figure 2). However, often 
in these cases, appropriate medical management 
recommendations with screening or risk-reduc-
ing measures are based on patient personal and 
family histories, in conjunction with other bio-
logic and behavioral risk factors (such as breast 
density, age, obesity, alcohol intake, and smoking 
history), more so than genetic test results alone 
(Fecteau, Vogel, Hanson, & Morrill-Cornelius, 
2014; Hiraki, Rinella, Schnabel, Oratz, & Ostrer, 
2014). Caution should be taken when performing 
genetic testing through a multigene panel, which 
includes a mixed collection of genes with high, 
moderate, and low penetrance (see Figure 3), as 
interpretation of results for clinical significance 
could become a challenge.
The implications of each individual gene 
tested add to the complexity of multigene panel 
testing. Gene mutations often increase the risk 
for more than one type of cancer (i.e., BRCA2 
mutations can lead to an increased risk for breast 
cancer, ovarian cancer, prostate cancer, pancre-
atic cancer, male breast cancer, and melanoma). 
In addition, patients who undergo genetic test-
ing may learn they are at risk for a cancer that 
has limited or no effectual screening and preven-
tion measures or that invasive surgery (e.g., pro-
phylactic total gastrectomy for CDH1-mutation 
carriers or bilateral salpingo-oophorectomy for 
BRCA1/2-mutation carriers) is their greatest 
chance to decrease cancer risk. 
Lastly, not all gene mutations are pathogenic, 
and some genetic tests result in finding variants 
of unknown significance (VUS), in which practi-
tioners cannot determine whether a patient has 
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an inherited genetic component that increases 
cancer risk because the pathogenicity of the vari-
ant identified is unknown.
CONSIDERATIONS OF MULTIGENE 
PANEL TESTING
Advanced practitioners in oncology should 
be aware of the features of both individual and 
family histories that are characteristic of an un-
derlying germline mutation (see Table 2). The 
accurate collection of this information in a com-
plete cancer family history, along with subse-
quent construction and interpretation of a pedi-
gree, serves as a fundamental tool to perform an 
assessment of cancer genetic risk. Pedigrees are 
used to determine inheritance patterns, identify 
the family member most appropriate for testing, 
decide upon the appropriate genetic testing op-
tions, and create a plan for genetic testing in a 
family with a positive mutation (Lundy, Forman, 
Valverde, & Kessler, 2014).
A complete family history should include at 
least three generations of biologically related fam-
ily members, with information on ages, cause of 
death for those deceased, maternal and pater-
nal ethnicities, and cancer history with age of 
diagnosis at minimum (Wood et al., 2014). For 
any relative with cancer, the following additional 
information should also be obtained if at all pos-
sible: the primary site of each cancer with pathol-
ogy reports if available, age at diagnosis for each 
primary cancer, history of surgery or treatments 
that may have reduced the risk of cancer (i.e., bi-
lateral salpingo-oophorectomy in a premenopaus-
al woman significantly reduces the risk of ovarian 
and breast cancers, masking an underlying heredi-
tary predisposition), and carcinogenic exposures 
(e.g., smoking history). 
For relatives not affected with cancer, the fol-
lowing additional information might also aid in 
pedigree interpretation: history of any surgeries 
or medical treatments that may have reduced the 
individual’s risk of cancer, cancer-screening prac-
tices, known carcinogenic exposures, and any 
nonmalignant features associated with the sus-
pected syndrome. 
Without having this fundamental information, 
nongenetic professionals and genetic profession-
Figure 1. Genetic architecture of cancer risk. 
Adapted from National Cancer Institute (2015).
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Table 1. Overview of Multigene Panels
Cancer panel High-penetrance genes
Moderate-
penetrance 
genes Low-penetrance genes
Breast cancer example
BRCAplus-Expanded 
(Ambry Genetics)
BRCA1, BRCA2, CDH1, PTEN, 
TP53
ATM, CHEK2, 
PALB2
–
Colon cancer example
Lynch/Colorectal High-
Risk Panel (GeneDx)
APC, EPCAMa, MLH1, MSH2, 
MSH6, MUTYH, PMS2
– –
Comprehensive Cancer 
Panel example 
Comprehensive Cancer 
Panel (GeneDx)
APC, BMPR1A, BRCA1, 
BRCA2, CDH1, CDK4, 
CDKN2A, EPCAMa, MLH1, 
MSH2, MSH6, MUTYH, PMS2, 
PTEN, SMAD4, STK11, TP53, 
VHL
ATM, CHEK2, 
PALB2 
AXIN2, BARD1, BRIP1, 
FANCC, NBN, POLD1, 
POLE, RAD51C, RAD51D, 
SCG5/GREM1, XRCC2
Note. aHighly penetrant with MSH2.
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als alike run the risk of misinterpreting hereditary 
cancer risk.
Choosing a Genetic Test
With the clinical application of multigene 
panel testing, advanced practitioners, on the ad-
vice of certified genetic counselors, have the op-
tion of choosing one of the following: (1) a single-
gene test using Sanger sequencing, (2) a cancer- or 
syndrome-specific high-penetrant gene panel, (3) 
a cancer- or syndrome-specific high- and moder-
ate-penetrant gene panel, or (4) a comprehensive 
cancer gene panel. Multifactorial components 
can come into play when selecting an appropriate 
genetic test. 
First, one must consider the diagnostic ca-
pabilities of sequencing technology used and the 
suspected type of variation present. Next-gener-
ation sequencing may be an appropriate choice 
for suspected missense, nonsense, or frameshift 
(insertions and deletions of base pairs) genetic 
alterations because of its ability to detect single 
base-pair substitutions, but not for phenotypes 
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40
35
25
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Low-penetrance genes tested
Moderate-penetrance genes tested
High-penetrance genes tested
Comprehensive
cancer panel
Syndrome-specific
panel (e.g., HBOC)
Cancer-specific
panel (e.g., breast)
Figure 3. Number of different genes tested ac-
cording to panel. A comprehensive panel tests 
more genes but includes more “low- 
penetrance” genes, for which clinical sig-
nificance of identified mutations is unknown. 
Conversely, a cancer-specific panel tests fewer 
genes, but the majority of genes have known 
clinical utility (e.g., high penetrance). HBOC = 
hereditary breast and ovarian cancer.
Figure 2. Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guide-
lines®) for Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 2.2016. © 2016 National Com-
prehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not 
be reproduced in any form for any purpose without the express written permission of the NCCN. To view the 
most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL COMPREHEN-
SIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned 
by the National Comprehensive Cancer Network, Inc.
NCCN Guidelines Index 
Genetics Table of Contents
Discussion
Note:  All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial.  Participation in clinical trials is especially encouraged.
NCCN Guidelines Version 2.2016 
Genetic/Familial High-Risk Assessment: Breast and Ovarian
ADDIT-2
BREAST AND OVARIAN MANAGEMENT BASED ON GENETIC TEST RESULTSa
aOther genes may be included in multi-gene testing.
bIntervention may still be warranted based on family history or other clinical factors.
cInsufficient evidence for any recommendations for breast MRI, RRSO, or RRM include but are not limited to: 
BARD1, FANCC, MRE11A, MUTYH, NF1, NBN, RAD50, SMARCA, or XRCC2.
dSee NCCN Guidelines for Breast Cancer Screening and Diagnosis.
eMay be modified based on family history or specific gene mutation.
fSee NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal.
RRM: risk-reducing mastectomy 
RRSO: risk-reducing salpingo-oophorectomy
Recommend Breast MRId
(>20% risk of breast cancere)
Discuss Option of RRM Recommend/Consider RRSO
Intervention 
warranted based on 
gene and/or risk level
ATM
BRCA1
BRCA2
CDH1
CHEK2
PALB2
PTEN
STK11
TP53
BRCA1
BRCA2
CDH1
PTEN
TP53
PALB2
BRCA1
BRCA2
Lynch syndromef
BRIP1
RAD51C
RAD51D
Insuffi cient evidence 
for interventionb,c
BRIP1 ATM
CHEK2
STK11
PALB2
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commonly caused by trinucleotide repeats 
or chromosomal abnormalities (Facio, Lee, & 
O’Daniel, 2014). 
Second, multigene panel testing should be 
considered in certain clinical scenarios (see 
Table 3). Finally, influences of genetic result 
turnaround time, patient out-of-pocket cost, 
insurance coverage, percentage rate for VUS, 
patient-perceived benefit of testing and interest 
in expanding testing options, and patient fear of 
genetic discrimination for insurance and/or em-
ployment all need to be considered and discussed 
with patients during a counseling session to col-
laboratively come to a decision about testing and 
which method to employ.
The NCCN Guidelines do not endorse multi-
gene panel testing as a superior option to sequen-
tial single-gene testing. However, they do recog-
nize that multigene panel testing may be a more 
efficient and/or cost-effective option for patients 
with a personal or family history suggestive of a 
single inherited cancer syndrome or when more 
than one gene could explain that inherited cancer 
syndrome. In addition, the Guidelines state there 
is a role for multigene testing in individuals who 
have tested indeterminate for a single syndrome 
but whose personal or family history remains 
strongly suggestive of hereditary cancer (NCCN, 
2016, p. GENE-1).
Presenting multigene panel testing as an op-
tion is often driven by genetic professionals’ clini-
cal judgment and weighing the benefits and limi-
tations with the perceived clinical utility in the 
setting of a patient’s personal and family histories 
(Selkirk et al., 2014). Providers can also assess a 
patient’s perception about genetic risk, motiva-
tors for genetic testing, tolerance of probabilistic 
information or ambiguity in test results, and un-
derstanding how results may impact family mem-
bers to determine whether panel testing would be 
appropriate (Cameron & Muller, 2009).
BENEFITS AND LIMITATIONS OF  
MULTIGENE PANEL TESTING
Case Study 1: Colon Cancer
The proband is a 70-year-old male with a 
medical history of colon cancer at the age of 48 
and numerous (~25) lifetime adenomatous polyps 
identified through colonoscopy screening (Fig-
ure 4). Pedigree evaluation revealed the follow-
ing pertinent family history: a paternal uncle with 
prostate cancer (unknown age of diagnosis) and 
no other family members with a known cancer or 
polyp history. At the time of referral for counsel-
ing, tumor samples were unavailable, and it was 
unknown whether microsatellite instability (MSI) 
and/or immunohistochemistry (IHC) tumor test-
ing was performed at the time of diagnosis.
His personal polyp history and age at cancer 
diagnosis are the only details suggestive of he-
reditary disease, with Lynch syndrome (gene mu-
tations in the mismatch repair genes of MLH1, 
MSH2, MSH6, PMS2, or EPCAM) or a polyposis 
syndrome (gene mutations in APC or MUTYH) 
suspected. The proband underwent genetic test-
ing with a colon cancer gene panel, which con-
sisted of genes from both syndromes; it resulted 
in an unexpectedly positive deleterious mutation 
in PMS2.
Multigene panel testing greatly benefited this 
patient and his family. If a single-gene approach 
to testing was utilized in this scenario, practitio-
ners would have likely started with the APC or 
MUTYH gene based on his adenoma history and 
Table 2. Features Suggestive of Hereditary Cancer
Individual patient Patient’s family
 • Early age at disease onset
 • Multiple primary cancers in the same organ
 • Multiple primary cancers in different organs
 • Bilateral disease in paired organs
 • Multifocal disease
 •  Gender not usually affected (e.g., male breast 
cancer)
 Two or more first-degree relatives on same side 
of family with:
 • Cancer of the same site
 •  Cancer types belonging to a known hereditary 
cancer syndrome 
 • Rare cancers
 •  Evidence of autosomal-dominant transmission 
Note. Information from Roesser (2010).
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then moved on to the mismatch repair genes of 
Lynch syndrome. It is possible that testing fatigue 
or cost may have deterred the patient from testing 
beyond a few genes, and the PMS2 mutation may 
have been left undiscovered.
PMS2 mutations carry a cancer risk of 15% to 
20% for colon cancer and 12% to 15% for endo-
metrial cancer compared with that of the general 
population (ten Broeke et al., 2015; Ambry Genet-
ics, 2016). With identification of a positive mu-
tation in the family, the brother and children of 
the proband should all consider genetic testing 
for the PMS2 mutation, as there are surveillance 
recommendations for colon and extracolonic 
cancer risks (refer to NCCN, 2015, p. LS-3 and 
LS-4). His children are all of appropriate age for 
colonoscopy screenings and may require them 
more frequently (every 1–2 years), and his daugh-
ters could benefit from increased endometrial 
cancer surveillance if they are found to carry the 
PMS2 mutation.
Other Benefits
Costs of gene panel testing continue to de-
crease due to advances in technology, increas-
ing utilization, and competitive market forces; 
as a result, it may prove to be a cost-effective op-
tion for some patients who could benefit from 
concurrent analysis of more than one gene. It 
also reduces the diagnostic odyssey for families 
meeting testing criteria for more than one hered-
itary syndrome.
Table 3. Clinical Scenarios That May Be Appropriate for Multigene Panel Testing
 •  Personal/family cancer history meets 
criteria for more than one hereditary cancer 
syndrome
 • Personal history of multiple cancer diagnoses
 • First-line testing is inconclusive
 • Truncated family history due to:
Unknown family history due to adoption
A large number of family members who died at 
a young age unrelated to cancer
Pedigree is predominately one gender, lacking 
representation of the opposite sex
Note. From National Cancer Institute (2015).
Figure 4. Identification of a PMS2 gene mutation in the proband. TAH-BSO = total abdominal hysterec-
tomy bilateral salpingo-oophorectomy; A&W = alive and well. 
3 4
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96 yr 
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93 yr
d. natural
d. unknown
d. young
70 yr
d. stroke
No colonoscopy
Proband, 70 yr
Colon cancer, 48 yr
Adenomatous polyp of colon
Onset: 48 yr
~25 lifetime adenomas
A&W
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Carcinoma of  
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TAH-BSO 40s
15 yr
d. accident
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No cancer
Heart disease
72 yr
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Basal cell carcinoma of face
A&WA&W, 40 yr
Colonoscopy- 
no polyps
No TAH-BSO
A&W, 44 yr
Colonoscopy- 
no polyps
No TAH-BSO
53 yr
Heart disease
Colonoscopy- 
no polyps 
38 yr
No colonoscopy
3
Colon cancer
Adenomatous polyp of colon
Basal cell carcinoma of face
Carcinoma of prostate
3
Norwegian Swedish
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Coverage for genetic testing is left to the dis-
cretion of each individual insurance company. 
Thus, a benefit of cancer multigene panels may 
be testing for all potential hereditary causes with 
a one-time insurance review. For example, in the 
Medicare population, insurance coverage policy 
restricts genetic testing to just one occurrence; 
therefore, if patients who had Medicare cover-
age for BRCA1 and BRCA2 analysis and received a 
negative result for a mutation in either gene, they 
would have out-of-pocket expenses for any fur-
ther testing unless they met criteria for a separate 
hereditary cancer syndrome.
The capabilities of multigene panel testing 
should be considered with the knowledge of its 
limitations. Technologic advances have outpaced 
our understanding of the human genome, as ge-
netic variations are being rapidly discovered in 
which their effect on gene function are presently 
unknown; thus, they often produce results that are 
yet to be clinically actionable.
Case Study 2: Ovarian Cancer
The proband is a 50-year-old female who was 
referred for genetic risk assessment due to a per-
sonal history of ovarian cancer, diagnosed at age 48 
(Figure 5). Pedigree evaluation revealed the follow-
ing pertinent family history: four family members 
with colon cancer, three in their 60s and her mom at 
age 53; a maternal aunt with both primary colon and 
breast cancers; a maternal uncle with both primary 
colon and prostate cancers; and her mom under-
went total abdominal hysterectomy with ovaries left 
intact. The sheer number and spectrum of primary 
cancers reported in this family are suspicious for a 
hereditary gene mutation.
The proband decided to undergo genetic testing 
with a comprehensive cancer panel, and the results 
identified a VUS in the CHEK2 gene. For VUS, it is 
undetermined whether the changes in DNA sequence 
and structure alter protein and gene function (i.e., the 
clinical significance of the DNA variation is unknown; 
Domchek, Bradbury, Garber, Offit, & Robson, 2013).
Unfortunately for this proband and family, with 
this result, cancer risk and recommendations for 
screening and risk-reducing measures can only be 
determined in the context of the family history and 
any other personal risk factors. Screening recom-
mendations for other cancers (colorectal, breast) 
should be followed. In the event the CHEK2 gene 
mutation had been classified as deleterious, there is 
a twofold increase in lifetime breast cancer risk, but 
the level of risk for other associated cancers such as 
colon, ovarian, kidney, and thyroid is unknown (Ra-
inville & Rana, 2014). The knowledge surrounding 
genes and their associated cancer risks and the abil-
ity to classify variants are constantly evolving. For 
this clinical case, medical management could one 
day change as more information becomes available.
Limitations
A major limitation of multigene panel testing 
is that the chance of identifying a VUS is propor-
tional to the number of genes tested (Fecteau et 
al., 2014). This fact can heighten patient anxiety 
and distress in addition to the increased chance of 
discovering cancer risk for which the patient was 
not expecting and identification of a gene muta-
tion of low clinical utility because penetrance is 
low or unknown (Kurian et al., 2014).
Next-generation sequencing technology can 
also have less accuracy than conventional se-
quencing methods and therefore requires confir-
mation testing of any pathologic variant before 
this information can be translated into patient 
care. Moreover, no matter how advanced se-
quencing technology becomes, it is not possible 
to completely rely on standard human reference 
sequences, because there will always be genomic 
variation due to common epigenomic changes 
and intratumour heterogeneity (Javitt & Carner, 
2014; Ulahannan, Kovac, Mulholland, Cazier, & 
Tomlinson, 2013).
Lastly, some commercial health-care insur-
ance plans have labeled genetic cancer suscepti-
bility panels using NGS as investigational and will 
not provide coverage for it, although the genetic 
counseling services may be covered. Other insur-
ance plans have identified that all components of 
the gene panel have to be considered medically 
necessary following this set of criteria: the genetic 
disorder is associated with malignancy; the risk of 
the cancer cannot be identified through biochemi-
cal or other testing; a specified mutation or set of 
mutations has been established in the scientific 
literature to be reliably associated with the risk 
of developing malignancy; the results of the ge-
netic test impact the medical management of the 
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individual being tested; the use of the genetic re-
sult in directing therapeutic decisions will likely 
result in an improvement in health and outcomes 
(Anthem, 2015). Some insurance providers re-
quire genetic counseling prior to covering genetic 
testing services.
Insurance Challenges and Coverage
Insurance companies frequently reference 
the NCCN Guidelines to guide their coverage de-
cisions and as described previously, the NCCN 
recommends multigene panel testing only in cer-
tain clinical scenarios (NCCN, 2016, p. GENE-1). 
Successful and complete integration of multigene 
panel testing into clinical practice will require 
clinical utility evidence, assessing whether the 
information produced by multigene panel tests 
improves patient health outcomes (i.e., increases 
survival) in comparison to conventional sequenc-
ing methods. Clinical utility is also the gold stan-
dard applied by most payers when evaluating tests 
for coverage and reimbursement decision-making 
(Deverka & Dreyfus, 2014).
The current pace of technology development 
in NGS has left payers with limited ability to deter-
mine whether a test meets quality standards (i.e., 
analytic validity) and clinical utility. Most clinical 
NGS tests are performed as laboratory-developed 
tests (LDTs) and do not have direct governmental 
oversight by the US Food and Drug Administra-
tion, in which proponents of this regulation view 
as a safety concern (Deverka & Dreyfus, 2014). In-
stead, LDTs are performed in clinical laboratories 
that have obtained a Certificate of Compliance 
or a Certificate of Accreditation under the Clini-
cal Laboratory Improvement Act (CLIA) of 1988, 
which is overseen by the Centers for Medicare & 
Medicaid Services (Deverka & Dreyfus, 2014; Ja-
vitt & Carner, 2014).
To ensure that the quality, accuracy, and reli-
ability of services and the safety of patients are up-
held, CLIA aims to measure the analytic validity of 
any test processed in a certified laboratory. How-
ever, there is no current formal CLIA-approved 
proficiency testing program for NGS, necessitat-
ing organizations such as the College of Ameri-
can Pathologists (CAP) and the American Col-
lege of Medical Genetics and Genomics (ACMG) 
to develop professional laboratory standards and 
guidelines (Bennett & Farah, 2014; Deverka & 
Dreyfus, 2014). The ACMG released standards for 
NGS in sample preparation, test ordering, test de-
velopment and validation, staff qualifications, data 
storage of patient information, and reporting of 
findings (Rehm et al., 2013).
The certification process for insurance cover-
age approval of genetic testing is typically submit-
ted by the laboratory. Most of the major laborato-
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ries that offer panel testing will notify the patient 
of out-of-pocket cost greater than $100 to $375, to 
obtain authorization prior to initiating analysis. In 
terms of reimbursement, Current Procedural Ter-
minology (CPT) codes related to genetic services 
fall into either laboratory or professional services. 
Currently, there are no molecular diagnostic codes 
that describe NGS sequencing, so gene panels are 
being billed using nonspecific CPT codes. Given 
the concerns with lack of transparency in genetic 
test ordering, the American Medical Association 
aims to develop NGS-specific CPT codes (Deverka 
& Dreyfus, 2014).
IMPLICATIONS FOR ONCOLOGY APs
Advanced practitioners in cancer care utilize 
many skills of a genetic counselor in their ability to 
gather a detailed family history, evaluate hereditary 
cancer risk, and provide psychosocial support. But 
additionally, they hold responsibility for managing 
patients’ care from the time of diagnosis, through 
treatment, and into survivorship or end of life. It 
is essential for APs to understand how inherited 
gene mutations can impact medical management 
decisions for treatment, risk-reduction methods, 
and surveillance measures, so specific interven-
tions can be incorporated into the plan of care, 
providing optimal patient outcomes. In current 
practice, many APs are not credentialed as genetic 
professionals, often making a referral for genetic 
risk assessment, counseling, and testing services. 
However, this practice may not be sustainable with 
growing public awareness and demand for genetic 
testing, expanding clinical applications, and de-
clining genetic testing costs.
Advanced practitioners will play increasing 
roles in the facilitation of genetic services and 
should engage in a more active role in risk as-
sessment and evaluation of family histories. They 
can provide genetic education, counseling, and 
testing within their licensure, scope of practice, 
expertise, and clinical setting (Greco et al., 2011). 
The ability to incorporate germline genetic infor-
mation into patient care is an essential part of on-
cology practice and essential competency for APs 
(Robson et al., 2015).
Several studies indicate that health-care pro-
viders, who do not specialize in genetics, generally 
lack the essential knowledge to provide genetic 
counseling and testing services. Although genet-
ic knowledge may be higher in certain specialty 
areas, such as oncology or pediatrics, even these 
providers may have deficiencies with respect to 
genetic information, especially in light of advance-
ment in genetic testing technology (Bensend, 
Veach, & Niendorf, 2014). The consequence of 
having health-care providers unprepared for com-
plex issues related to multigene panel testing and 
genomics in general may be inaccurate cancer risk 
assessment and erroneous test selection and result 
interpretation (Mahon, 2012). These types of er-
rors can result in negative patient outcomes, such 
as inappropriate medical management, unneces-
sary risk-reducing surgeries, excessive testing, and 
psychosocial distress.
Educators across every health-care discipline 
struggle to incorporate genetic/genomic content 
into an already-crowded curriculum, and practitio-
ners whose education predated the genomic era are 
challenged to keep current on changes in genetic 
technology (Greco et al., 2011). The American Nurs-
es Credentialing Center (ANCC) offers credentialing 
to nurses’ postgraduate education to obtain board 
certification as an advanced genetics nurse. Obtain-
ing this level of proficiency will be necessary in the 
future (Chowdhury et al., 2015), as genetic/genomic 
science becomes the mainstay of modern medicine.
CONCLUSION
Multigene panel testing for inherited cancer 
risk assessment is being rapidly integrated as a new 
approach to genetic testing. With this technology 
comes the potential to reveal genetic variations 
that have uncertainty regarding cancer risk and 
management decisions. Given the potential issues 
for patients and their families, multigene panel 
testing for inherited cancer risk is recommended 
to be preceded by genetic counseling and in con-
sultation with an experienced genetics profession-
al, which now is starting to incorporate APs. With 
cancer genomics and genetics leading the field of 
personalized medicine, oncology APs will need to 
assume clinical and educator roles to translate ge-
nomic/genetic health into clinical practice. l
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